190 related articles for article (PubMed ID: 21117680)
1. Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases.
Meshkat S; Klon AE; Zou J; Wiseman JS; Konteatis Z
J Chem Inf Model; 2011 Jan; 51(1):52-60. PubMed ID: 21117680
[TBL] [Abstract][Full Text] [Related]
2. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
5. CORES: an automated method for generating three-dimensional models of protein/ligand complexes.
Hare BJ; Walters WP; Caron PR; Bemis GW
J Med Chem; 2004 Sep; 47(19):4731-40. PubMed ID: 15341488
[TBL] [Abstract][Full Text] [Related]
6. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
7. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations.
Tominaga Y; Jorgensen WL
J Med Chem; 2004 May; 47(10):2534-49. PubMed ID: 15115396
[TBL] [Abstract][Full Text] [Related]
8. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
[TBL] [Abstract][Full Text] [Related]
9. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
Chuaqui C; Deng Z; Singh J
J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
[TBL] [Abstract][Full Text] [Related]
10. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
Jacobs MD; Caron PR; Hare BJ
Proteins; 2008 Mar; 70(4):1451-60. PubMed ID: 17910071
[TBL] [Abstract][Full Text] [Related]
11. Protein flexibility in ligand docking and virtual screening to protein kinases.
Cavasotto CN; Abagyan RA
J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
[TBL] [Abstract][Full Text] [Related]
12. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
[TBL] [Abstract][Full Text] [Related]
14. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
Deng Z; Chuaqui C; Singh J
J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
[TBL] [Abstract][Full Text] [Related]
15. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
[TBL] [Abstract][Full Text] [Related]
16. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
17. Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study.
Panigrahi SK
Amino Acids; 2008 May; 34(4):617-33. PubMed ID: 18180869
[TBL] [Abstract][Full Text] [Related]
18. Modeling and selection of flexible proteins for structure-based drug design: backbone and side chain movements in p38 MAPK.
Subramanian J; Sharma S; B-Rao C
ChemMedChem; 2008 Feb; 3(2):336-44. PubMed ID: 18081134
[TBL] [Abstract][Full Text] [Related]
19. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.
Jahnke W; Blommers MJ; Fernández C; Zwingelstein C; Amstutz R
Chembiochem; 2005 Sep; 6(9):1607-10. PubMed ID: 16028302
[No Abstract] [Full Text] [Related]
20. Structure of the regulatory domains of the Src-family tyrosine kinase Lck.
Eck MJ; Atwell SK; Shoelson SE; Harrison SC
Nature; 1994 Apr; 368(6473):764-9. PubMed ID: 7512222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
